{"filings":[{"id":67841,"accession_number":"0000718937-26-000022","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2026-05-13T20:02:18+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STAAR Surgical Q1 net sales up 119.6% to $93.5M; returns to profitability with GAAP EPS $0.10","event_type":"earnings","confidence":"high","bullets":["Record Q1 net sales of $93.5M, up 119.6% YoY, driven by China recovery and U.S. growth.","GAAP net income $5.2M ($0.10 diluted EPS) vs net loss of $54.2M ($1.10 loss) a year ago.","Adjusted EBITDA $24.4M ($0.48/share) vs adjusted EBITDA loss of $26.3M in prior year.","Gross margin improved to 73.6% from 65.8%; operating expenses down 18% YoY.","China distributor inventory normalized; EVO+ ICL launch early demand exceeded expectations."],"consensus_eps_estimate":-0.065,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":93522000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98472,"accession_number":"0000718937-26-000009","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2026-04-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STAAR Surgical prelim Q1 2026 net sales expected >$90M, up from $42.6M YoY","event_type":"earnings","confidence":"high","bullets":["Net sales expected to exceed $90M in Q1 2026, more than double prior year's $42.6M.","China accounted for majority of increase; Americas delivered double-digit growth.","Significant cost-structure improvement expected to drive meaningful adjusted EBITDA increase.","Middle East & parts of EMEA/APAC saw sales decline due to geopolitical/macro headwinds.","Full Q1 results and 10-Q to be reported in early May; no forward guidance provided."],"consensus_eps_estimate":-0.065,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":93522000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113966,"accession_number":"0000718937-26-000005","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STAAR Surgical appoints interim co-CEOs; reports China stabilization, EVO+ launch, cost cuts","event_type":"earnings","confidence":"low","bullets":["Warren Foust and Deborah Andrews named Interim Co-CEOs after Alcon merger rejected by shareholders in Jan 2026.","Cost reductions beat $225M second-half 2025 run rate target; operating expenses lowered significantly.","China EVO ICL demand recovered at mid-single-digit rate in 2025; distributor inventories normalized.","EVO+ received China regulatory approval mid-2025; early demand exceeds expectations; shipments began Nov 2025.","FDA expanded EVO ICL age range to 21-60 in US, adding ~8M potential patients; new SVP hires in supply chain and APAC."],"consensus_eps_estimate":0.0583,"consensus_eps_actual":-1.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":239442000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113965,"accession_number":"0001193125-26-038534","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"STAAR Surgical CLO Nathaniel Sisitsky departs; receives severance and consulting deal","event_type":"leadership","confidence":"high","bullets":["Nathaniel Sisitsky terminated as Chief Legal Officer and Corporate Secretary effective Feb 4, 2026; treated as termination without cause.","Severance includes 12 months base salary, 12 months insurance premium reimbursement, 2025 annual bonus, and $75,000 retention award installment.","Consulting agreement runs through March 13, 2026 at $8,000/week plus $10,000 completion fee for transition of legal function.","March 2026 RSUs accelerated and vested; all other equity awards (options, PSUs, other RSUs) forfeited as of Separation Date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113964,"accession_number":"0001193125-26-032630","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"STAAR Surgical appoints interim co-CEOs after CEO Farrell steps down; global CEO search launched","event_type":"leadership","confidence":"high","bullets":["Stephen C. Farrell stepped down as CEO effective Jan 31, 2026, per prior cooperation agreement with Broadwood Partners.","Warren Foust (President/COO) and Deborah Andrews (CFO) named interim co-CEOs effective Feb 1, 2026.","Board's Search Committee launched global CEO search; internal and external candidates considered.","Foust and Andrews each awarded $375,000 in RSUs vesting Aug 1, 2026, for interim service.","Foust's letter agreement includes additional severance if not offered permanent CEO role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113963,"accession_number":"0001193125-26-014681","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"STAAR Surgical elects new Board Chair; forms CEO Search Committee","event_type":"leadership","confidence":"high","bullets":["Neal C. Bradsher (Broadwood Capital, largest stockholder) elected Board Chair effective Jan 15, 2026.","Board creates Search Committee to identify CEO successor; chaired by Lilian Y. Zhou.","New Insight and Engagement Committee formed to gather business perspectives; chaired by Christopher M. Wang.","All directors determined independent; Audit Committee regains NASDAQ compliance.","Standing committee chairs: Audit (Zhou), Compensation (Silverman), Nominating & Governance (Bradsher)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113962,"accession_number":"0001193125-26-013622","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["1.01","3.01","5.02","8.01","9.01"],"status":"ready","headline":"STAAR Surgical CEO Farrell to step down Jan 31; Broadwood appoints three new directors","event_type":"leadership","confidence":"high","bullets":["CEO Stephen Farrell to step down as CEO by Jan 31, 2026; will remain as consultant for 1 year at $45k/month.","Board expands from 6 to 7; Neal Bradsher and Richard LeBuhn (Broadwood, 31% owner) and Christopher Wang (Yunqi Capital, 6.5%) appointed.","Elizabeth Yeu resigns as Board Chair and director; Board seeks new Chair and CEO.","NASDAQ audit committee noncompliance due to Yeu resignation; Company using cure period.","Cooperation agreement includes standstill until June 18, 2026; mutual non-disparagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113961,"accession_number":"0001193125-26-004699","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["1.02","5.07"],"status":"ready","headline":"STAAR Surgical's merger with Alcon terminated after shareholder vote; no fee","event_type":"m_and_a","confidence":"high","bullets":["Merger agreement with Alcon terminated effective Jan 6, 2026; no termination fee payable.","Special meeting held same day; 87.9% of shares represented (43,367,928 of 49,365,823).","Merger proposal not approved: 14,904,915 For, 27,339,877 Against, 1,123,136 abstain.","Compensation proposal not approved: 14,224,065 For, 27,905,792 Against, 1,238,071 abstain.","Both parties bear their own costs and expenses under the Merger Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113960,"accession_number":"0001193125-26-003534","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"STAAR Surgical shareholders vote down Alcon merger; deal terminated","event_type":"m_and_a","confidence":"high","bullets":["Preliminary vote tally failed to secure enough shareholder approval for the Alcon merger at special meeting on Jan 6, 2026.","STAAR will terminate the merger agreement with Alcon; no termination fee payable by either party.","Company remains standalone publicly traded (STAA); CEO Stephen Farrell highlights focus on EVO ICL technology and profitable growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130375,"accession_number":"0001193125-25-311982","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Alcon raises STAAR Surgical acquisition price to $30.75 per share from $28.00","event_type":"m_and_a","confidence":"high","bullets":["Merger consideration increased to $30.75/share in cash, up from $28.00/share (approx. 9.8% increase).","Amendment treats RSUs and PSUs as Alcon equity awards; PSUs deemed earned at 100% of target.","Amendment eliminates 280G gross-up and related tax indemnification arrangements.","Deal requires stockholder approval and regulatory clearances; proxy statement filed September 16, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130374,"accession_number":"0001193125-25-310631","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"STAAR's go-shop period expires with no competing bids; 21 parties contacted, none submitted proposal","event_type":"m_and_a","confidence":"high","bullets":["Go-shop period expired December 6, 2025; no competing acquisition proposals received.","STAAR engaged 21 third parties; two signed NDAs and received diligence, but no proposals.","Broadwood's claims of interest from Party A, B, C not substantiated; none signed NDAs.","Board says result validates process; Alcon is the right buyer for STAAR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130373,"accession_number":"0001193125-25-271708","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"STAAR Surgical amends Alcon merger: 30-day go-shop, no termination fee for qualified bidders, meeting postponed","event_type":"m_and_a","confidence":"high","bullets":["30-day go-shop period through Dec 6, 2025; STAAR may actively solicit third-party proposals.","No termination fee payable if STAAR terminates for a superior proposal from a qualified bidder.","Alcon waives matching rights and information rights during the go-shop period.","Special stockholder meeting postponed to Dec 19, 2025; record date remains Oct 24, 2025.","Alcon to engage STAAR stockholders and proxy advisors to solicit support for the merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130372,"accession_number":"0001193125-25-266857","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STAAR Surgical Q3 2025 earnings: press release content not provided in filing text","event_type":"earnings","confidence":"low","bullets":["The 8-K filing incorporates a press release by reference but no financial figures are included in the submitted text.","Investors should consult the full press release for specific revenue, EPS, and guidance details.","Confidence is low because the actual earnings data is not available for summarization.","The filing covers quarter ended September 26, 2025; date of report is November 5, 2025."],"consensus_eps_estimate":0.1647,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":181641000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130371,"accession_number":"0001193125-25-250959","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"STAAR postpones special meeting on Alcon merger to Dec 3 amid ongoing discussions","event_type":"m_and_a","confidence":"high","bullets":["Special meeting of stockholders postponed from Nov 6 to Dec 3, 2025; new record date: Oct 24, 2025.","Postponement is in light of ongoing discussions with Alcon (NYSE: ALC) regarding the merger agreement.","Stockholders who held shares as of Oct 24 close are eligible to vote at the Dec 3 meeting.","Proxy solicitor Innisfree M&A available for questions; STAAR will send updated meeting materials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130370,"accession_number":"0001193125-25-248797","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"STAAR adjourns special meeting on Alcon merger to Nov 6, 2025","event_type":"m_and_a","confidence":"high","bullets":["Special meeting scheduled for Oct 23, 2025 adjourned to 8:30 a.m. PT on Nov 6, 2025.","Record date for voting remains September 12, 2025; no other business conducted.","Shareholders with questions can contact Innisfree M&A Incorporated toll-free at 877-750-8233.","Alcon (ALC) and STAAR (STAA) agreed on the adjournment; no reason provided for delay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130369,"accession_number":"0001193125-25-243041","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STAAR Surgical announces preliminary Q3 net sales $94.7M (+6.9%); includes $25.9M China shipment","event_type":"earnings","confidence":"high","bullets":["Preliminary net sales $94.7M, up 6.9% YoY from $88.6M; outside China grew 7.7%.","$25.9M from December 2024 China ICL shipment recognized in Q3 upon payment receipt.","China distributors reduced inventory by ~$80-85M over nine months; new Q3 orders fell.","Distributor inventory at ~6 months as of Sep 26, aligned to contractual levels.","Special meeting Oct 23 to vote on Alcon merger proposal; early release for stockholders."],"consensus_eps_estimate":0.1647,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":181641000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130368,"accession_number":"0001193125-25-238127","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"STAAR Surgical supplements proxy for Alcon merger; faces lawsuits, Broadwood opposition","event_type":"other_material","confidence":"high","bullets":["Two shareholder lawsuits filed Oct 1 in NY state court alleging proxy misrepresentations; demand letters also received.","STAAR voluntarily supplements proxy with additional disclosure; believes claims without merit but seeks to avoid delay.","Broadwood (27.3% holder) opposes merger; Soleus (6%) supports; Yunqi (5.1%) opposes. No competing proposals received.","Special meeting to vote on merger scheduled Oct 23, 2025; $28.00 per share consideration unchanged.","Citi's DCF analysis implied per share range $17.70-$37.50; selected precedent transactions EV/LTM revenue 3.1x-6.3x."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146919,"accession_number":"0001193125-25-218827","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STAAR urges stockholders to vote FOR Alcon merger at $28/sh, citing 59% VWAP premium","event_type":"m_and_a","confidence":"high","bullets":["Alcon merger offers $28.00 per share cash; 51% premium to Aug 4 close, 59% to 90-day VWAP.","Second-largest active holder Soleus Capital (≈6% stake) supports merger and intends to vote FOR.","45-day window shop expired Sep 19; no competing acquisition proposals were received.","Board warns standalone stock would fall from $18.49 pre-announcement amid declining China sales and competition.","Broadwood's claims called flawed; STAAR ranks last in 2024-2027E net sales CAGR vs peer set."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146918,"accession_number":"0000950170-25-103974","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STAAR Surgical announces Q2 2025 earnings; no specific figures in filing","event_type":"earnings","confidence":"low","bullets":["The 8-K filing references a press release but the exhibit text is not provided in the excerpt.","No revenue, EPS, or segment data are available from the filing body alone.","Investors should refer to the full press release for actual financial results."],"consensus_eps_estimate":-0.6743,"consensus_eps_actual":-1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":86909000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146917,"accession_number":"0001193125-25-173090","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Alcon to acquire STAAR Surgical for $28/share in cash, ~$1.5B equity value","event_type":"m_and_a","confidence":"high","bullets":["Alcon pays $28/share cash, a ~59% premium to STAAR's 90-day VWAP and 51% premium to Aug 4 close.","Transaction valued at ~$1.5B equity; Alcon will fund via short- and long-term credit facilities.","Expected to close in 6–12 months, subject to regulatory approvals and STAAR shareholder vote.","STAAR's board unanimously approved; deal is not subject to financing condition and expected to be accretive in year two.","STAAR will release Q2 results on Aug 6, 2025 but will not host a conference call due to pending acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165410,"accession_number":"0000950170-25-089733","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"STAAR Surgical appoints Deborah Andrews permanent CFO, forms Capital Stewardship Committee, IR head leaves","event_type":"leadership","confidence":"high","bullets":["Deborah Andrews appointed CFO effective June 25, 2025; she served as interim CFO since March 2025 and previously held the role from 2007-2013 and 2017-2020.","Compensation: base salary $495k, target bonus 55%, equity award valued at $1.4M (50% RSUs vesting over 3 years, 50% PSUs tied to revenue targets through 2027).","Company on track to achieve $225M annual SG&A run rate ahead of schedule.","Board forms new Capital Stewardship Committee chaired by Lilian Y. Zhou to guide capital allocation and oversight.","Brian Moore, VP Investor Relations and Corporate Development, will depart effective June 27, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165409,"accession_number":"0000950170-25-087967","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"STAAR Surgical annual meeting results: all six directors elected, auditor ratified, say-on-pay approved","event_type":"other","confidence":"high","bullets":["All six director nominees elected: highest votes 42.1M (Farrell, Silverman), lowest 41.1M (Butcher); broker non-votes 2.5M each.","Ratification of BDO USA as auditor for FY2026: 44.5M for, 273k against, 10.5k abstain.","Non-binding advisory vote on NEO compensation approved: 41.1M for, 1.05M against, 24.7k abstain, 2.5M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165408,"accession_number":"0000950170-25-081391","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STAAR Surgical posts investor presentation with no new material disclosures","event_type":"other_material","confidence":"low","bullets":["Presentation dated June 4, 2025 reiterates STAAR as global leader in phakic IOLs.","Slides address the global myopia epidemic; no specific financial or guidance data provided.","Furnished under Regulation FD; not filed and not incorporated by reference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165407,"accession_number":"0000950170-25-073099","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"STAAR Surgical announces $30M buyback and China NMPA approval for EVO+ TICL","event_type":"other_material","confidence":"high","bullets":["Authorized $30M share repurchase program, expected to run over six months from cash on hand.","Company had $222.8M cash and equivalents, no debt as of March 28, 2025; ~49.5M shares outstanding.","China's NMPA approved EVO+ Toric ICL for myopia correction (-0.5D to -18D, astigmatism ≤6D).","EVO+ spheric ICL application remains pending with NMPA; Switzerland manufacturing validations ongoing for China supply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}